OncoCyte Co. (NASDAQ:OCX) Shares Acquired by Broadwood Capital Inc.

Broadwood Capital Inc. grew its stake in shares of OncoCyte Co. (NASDAQ:OCX) by 26.7% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 6,244,405 shares of the company’s stock after purchasing an additional 1,315,339 shares during the period. OncoCyte makes up 1.2% of Broadwood Capital Inc.’s investment portfolio, making the stock its 6th biggest holding. Broadwood Capital Inc. owned about 37.10% of OncoCyte worth $14,862,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors and hedge funds also recently made changes to their positions in the stock. Two Sigma Securities LLC acquired a new position in OncoCyte during the 4th quarter valued at about $31,000. FNY Investment Advisers LLC boosted its position in shares of OncoCyte by 15.1% during the fourth quarter. FNY Investment Advisers LLC now owns 49,377 shares of the company’s stock valued at $117,000 after buying an additional 6,481 shares during the last quarter. Geode Capital Management LLC grew its holdings in OncoCyte by 12.2% during the third quarter. Geode Capital Management LLC now owns 103,980 shares of the company’s stock worth $296,000 after buying an additional 11,289 shares in the last quarter. Finally, Pura Vida Investments LLC raised its position in OncoCyte by 32.1% in the 4th quarter. Pura Vida Investments LLC now owns 654,451 shares of the company’s stock valued at $1,558,000 after buying an additional 159,106 shares during the last quarter. Institutional investors own 55.35% of the company’s stock.

OncoCyte Stock Performance

Shares of OCX stock opened at $2.92 on Tuesday. The firm has a market cap of $83.51 million, a price-to-earnings ratio of -0.66 and a beta of 0.95. OncoCyte Co. has a 52 week low of $1.92 and a 52 week high of $4.75. The firm’s 50-day simple moving average is $3.17 and its two-hundred day simple moving average is $2.71.

OncoCyte (NASDAQ:OCX) last posted its quarterly earnings results on Monday, March 24th. The company reported $0.48 EPS for the quarter, topping analysts’ consensus estimates of ($0.40) by $0.88. OncoCyte had a negative net margin of 6,122.29% and a negative return on equity of 269.32%. The company had revenue of $1.49 million for the quarter, compared to analysts’ expectations of $0.16 million. Analysts forecast that OncoCyte Co. will post -2.57 earnings per share for the current year.

Insider Buying and Selling at OncoCyte

In other OncoCyte news, CFO Andrea S. James acquired 97,561 shares of OncoCyte stock in a transaction that occurred on Friday, February 7th. The stock was acquired at an average cost of $2.05 per share, for a total transaction of $200,000.05. Following the purchase, the chief financial officer now owns 151,231 shares of the company’s stock, valued at approximately $310,023.55. This represents a 181.78 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, major shareholder Patrick W. Smith bought 1,077,600 shares of the stock in a transaction on Friday, February 7th. The shares were acquired at an average cost of $2.05 per share, for a total transaction of $2,209,080.00. Following the acquisition, the insider now directly owns 2,872,671 shares in the company, valued at approximately $5,888,975.55. This trade represents a 60.03 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Corporate insiders own 1.58% of the company’s stock.

Wall Street Analyst Weigh In

Several analysts have recently issued reports on OCX shares. Stephens reiterated an “equal weight” rating and issued a $4.00 target price on shares of OncoCyte in a research note on Tuesday, March 25th. StockNews.com started coverage on shares of OncoCyte in a research note on Sunday, April 6th. They issued a “sell” rating for the company. Needham & Company LLC restated a “buy” rating and issued a $4.25 target price on shares of OncoCyte in a research note on Tuesday, April 8th. Finally, Lake Street Capital initiated coverage on OncoCyte in a research report on Friday, March 28th. They set a “buy” rating and a $5.00 price target for the company.

About OncoCyte

OncoCyte Corporation, a precision diagnostics company, focuses on development and commercialization of proprietary tests in the United States and internationally. The company is developing DetermaIO, a gene expression test that assesses the tumor microenvironment to predict response to immunotherapies; DetermaCNI, a blood-based monitoring tool for monitoring therapeutic efficacy in cancer patients; and VitaGraft, a blood-based solid organ transplantation monitoring test.